Sarepta Therapeutics (SRPT)
Health Care · Rare genetic disease therapeutics · NASDAQ
Sarepta is a rare-disease biotech focused on genetic therapies for muscular dystrophies, powered by antisense and gene therapy platforms.
What Sarepta Therapeutics does
Sarepta Therapeutics develops and commercializes therapies for rare genetic muscular dystrophies and other serious genetic diseases. The company markets several antisense oligonucleotide therapies for Duchenne muscular dystrophy (DMD) and has an approved gene therapy product for early-onset Duchenne muscular dystrophy. Sarepta generates revenue from product sales and strategic collaborations while investing heavily in research and development of pipeline candidates targeting monogenic rare diseases.
Themes: ["Rare genetic diseases / muscular dystrophies"]
Fundamentals
- Price$20.52 as of 2026-07-09 close
- Market cap$2.2B as of 2026-07-10
- 1-year return+5.9% as of 2026-07-09 close
- P/E33.07 as of 2026-07-10
- Net margin+3.0% as of 2026-07-10
- Gross margin+70.5% as of 2026-07-10
- ROE+4.9% as of 2026-07-10
- Debt / equity0.56 as of 2026-07-10
- Revenue growth (YoY)-2.2% as of 2026-07-10
- Revenue CAGR (3y)+33.1% SEC XBRL
- Beta0.18 as of 2026-07-10
Key risks (from latest filing)
["Revenue dependence on DMD therapies and potential market adoption challenges for approved products, evidenced by product revenue declining 46% YoY in Q1 2026"]
Competitors & peers
- Duchenne Muscular Dystrophy Alliance members and biotech partners
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.